La guía definitiva sobre edición genética.
Menú
Inicio Aprender Noticias Pregunta al Atlas
Explorar Tecnologías Enfermedades Tratamientos Ensayos clínicos Empresas Científicos Genes Investigación Instituciones
Más allá de la medicina Agricultura Ética Inversión Mapa mundial
Aprender y herramientas Empieza aquí Glosario A–Z Comparar tecnologías Cronología Listas y rankings Agentes de IA ★ Guardado API
Acerca de Quiénes somos Metodología Fuentes de datos Política editorial Contacto Avisos legales

🧭 Vista guiada
¿Eres nuevo en genética? Explicamos cada término mientras navegas, en un lenguaje sencillo. Las mismas páginas, con la ayuda incorporada.

⚡ Opinión experta
Ya conoces la biología. Solo el contenido — limpio y compacto, sin explicaciones adicionales. Esta es la vista predeterminada.

Idioma de la interfaz
Modo claro

Disease · Eye disease

Retinitis Pigmentosa

A group of inherited retinal degenerations with over 80 causative genes — where the obstacle is not delivery but the sheer number of different causes.

Preclinical eyeheterogeneous
Preclinical research Tested in cells and animals only. Most preclinical programmes never reach people, and animal results often do not carry over.

Explicación sencilla

Retinitis pigmentosa slowly destroys the light-sensing cells of the retina, usually starting with night vision and side vision. More than eighty different genes can cause it, and a treatment aimed at one of them helps only the people who have that particular fault. The eye is the easiest organ to reach, so here the hard part is not getting the treatment in — it is that there are dozens of separate diseases wearing one name.

Profundizar

Retinitis pigmentosa encompasses inherited rod-cone dystrophies caused by variants in more than 80 genes with autosomal dominant, recessive and X-linked inheritance. RHO, RPGR, USH2A and PDE6B are among the more common. Dominant-negative RHO variants are approached by allele-specific knockdown; loss-of-function forms by correction or gene addition. Mutation-agnostic strategies — optogenetic or neuroprotective — are pursued precisely because per-gene development is economically difficult across so many small populations.

The rare-disease economics problem, concentrated

Retinitis pigmentosa is the clearest illustration of a problem that runs through this whole field. The science for a given gene may be tractable; the population carrying that gene may be a few thousand people worldwide. The discontinuation of the CEP290 programme after a scientifically encouraging trial happened for exactly this reason. Regulators are now actively rethinking approval pathways for individualised therapies in response.

Sources

Connected in the Atlas

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Genes

CEP290
Solo información educativa Esta página es una referencia, no asesoramiento médico. El estado de la investigación y la situación regulatoria cambian; comprueba la fecha de última actualización que aparece arriba y confirma cualquier dato importante con las fuentes primarias indicadas.